Prostate cancer is one of the most troublesome types of cancers in the US, and all malignancies are best treated at an early stage when long-term survival is most probable. Unfortunately, prostate cancer may lack symptoms or signs in early stages, making detection difficult. Fortunately, we now have ways to detect prostate cancer before it progresses for the first time, thanks to earlier detection techniques.
Prostate-specific antigen (PSA) testing is still considered the best way to predict whether a man is at danger of developing prostate cancer or if he might already have it. A healthy man's serum PSA concentration represents not much beyond 4 ng/ml. A benign prostate tumor will have about a similar amount or even less PSA in its cells. Smaller, benign, slower growing prostates are known to have lower PSA than larger or actively growing ones.
The American Society of Clinical Oncology (ASCO) has determined that a serum alkaline phosphatase reading of above 105 U/L or a usisfractal-defined PSA below 0.25 ng/mL indicates low cancer risk in a blood test. Men who fall into this “gray zone” of risk, estimated to occur in 8% of post-menopausal men and in 1% of men ages 50-65 years, should return for extensive PSA and prostate-gland doctor examinations, executed by skilled ultrasonomic imaging technique personnel. Less rigorous examination procedures but guided by sustained serum PSA readings above 4ng/mL OR low prostate volumes of 2 mL OR recently experienced PSA test abnormality OR any finding during digital prostate examination suggest primary suspicion of prostate cancer in men.
Especially early-stage prostate cancer can usually be detected and treated right away, wanting to prevent the relapse and development of metastatic health issues. Ostensibly men within a higher risk group - estimated 9% of all men aged 60 years OR a history of clinically irrelevant precancerous prostate DNA-related aberrations - may beat cancer if they take regular multidimensional prostate medical examinations. Prescription of an initial diagnostic PSA examination might be put into action by men having a high risk profile where they have a 15-year disease-free lifetime expectancy OR would benefit from decisions on either active or supplemental prostate oncological treatment, including prostate LASIK procedure or radical surgical excision.